ABSTRACT
The aim of this study was to assess whether introduction of Docetaxel into the management will improve palliation of symptoms; quality of life; response rate and probably survival in breast cancer patients. A total of 19 patients referred from different medical centers in Nigeria were entered into the study. The age range was 25 to 52 years with a median of 34 years. The sex incidence was 18 females; 1 male. There were 7 patients in stage III and the duration of median response was 30 months. There were 12 patients in stage IV. Out of these 3 patients with brain metastasis had median response of 4 months. 4 patients with liver metastasis average duration of response was 22 months. 5 patients with pulmonary metastasis average duration of response was 20 months. In all; 16; out of the 19 patients (84
